Numeric Biotech

Numeric Biotech is a Dutch biotechnology company specializing in the development of senolytic therapies to combat age-related diseases and cancer. The company's core technology focuses on disrupting the interaction between the FOXO4 protein and p53, which triggers apoptosis in senescent cells while sparing healthy ones. Their lead candidate, a FOXO4-DRI peptide, has shown promise in reversing age-related phenotypes and treating aggressive tumors like glioblastoma. By targeting the secretome of senescent cells, Numeric Biotech aims to address the root causes of chronic inflammation and tissue degeneration. The company is a spin-off from Erasmus University Medical Center and operates within the emerging field of longevity science.